Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

High‐Dose Recombinant Canarypox Vaccine Expressing HIV‐1 Protein, in Seronegative Human Subjects

2005; Oxford University Press; Volume: 192; Issue: 7 Linguagem: Inglês

10.1086/432915

ISSN

1537-6613

Autores

Paul Goepfert, Helen Horton, M. Juliana McElrath, Sanjay Gurunathan, Guido Ferrari, Georgia D. Tomaras, David C. Montefiori, Mary Allen, Ya‐Lin Chiu, Paul Spearman, Jonathan D. Fuchs, Beryl A. Koblin, William A. Blattner, Sharon E. Frey, Michael C. Keefer, Lindsey R. Baden, Lawrence Corey,

Tópico(s)

Herpesvirus Infections and Treatments

Resumo

BackgroundIn clinical trials, canarypox ALVAC–human immunodeficiency virus (HIV) vaccines have been shown to elicit human HIV–specific cytotoxic T lymphocyte (CTL) responses in some but not all healthy uninfected adults

Referência(s)